Successful therapy of chimeric antigen receptor T cells for isolated extramedullary acute lymphoblastic leukemia

Xiangqun Li1 | Kylan Chen2 | Xian Zhang3,4 | Junfang Yang3,4 | Jianwei Zheng1 | Fei Dong1 | Yongbo Zhu1 | Jiao Yu1 | Peihua Lu3,4 | Bo Chen1

1Kecellitics Biotech Company Ltd, Beijing, China
2College of Natural Sciences, University of Texas, Austin, Texas, USA
3Lu Daopei Hospital, Langfang, Hebei, China
4Lu Daopei Institute of Hematology, Beijing, China

Correspondence
Bo Chen, Kecellitics Biotech Company Ltd, Beijing, China.
Email: bochen1008@outlook.com

Funding information
Kecellitics Biotech Company, a subsidiary of the Daopei Medical Group

Despite many clinical trials of CD19-targeted CAR T cells for the treatment of B-cell acute lymphoblastic leukemia (B-ALL) having been reported, few studies of CD19 CAR T therapy for isolated refractory/relapsed (r/r) extramedullary ALL (EM-ALL) patients have been published. Extramedullary involvement is considered an unfavorable prognostic factor, which often reduces leukemia response to induction chemotherapy and is usually associated with shorter progression-free survival (PFS) and overall survival (OS) [1, 2]. There is still no standard guideline on the treatment of isolated EM-ALL [3]. Considering the absence of leukemia blasts in the peripheral blood and bone marrow in isolated EM-ALL patients, the questions of whether CAR T cells can successfully expand in these patients and whether these patients can benefit from CD19 CAR T therapy remain unanswered. In this study, we evaluated the safety and efficacy of CD19 CAR T cells for isolated r/r EM-ALL patients (ChiCTR2000038532).

Our cohort enrolled nine refractory or relapsed isolated EM-ALL patients admitted to Hebei Yanda Lu Daopei Hospital between 2019 and 2021. The median age was 14 years old (ranging from 8 to 33). Among them, three isolated EM-ALL patients were confined to just CNS involvement. The other patients had more complicated EM involvement including liver, bone, lung, neck, or testis. The detailed characteristics are summarized in Table 1. Following leukapheresis, all patients received fludarabine (30 mg/m² per day) and cyclophosphamide (250 mg/m² per day) lympho-depleting chemotherapy for three consecutive days before the CD19 CAR T cell infusion. As for the patients with CNS infiltration, intrathecal chemotherapy was performed to reduce blasts in the cerebrospinal fluid (CSF) before CAR-T cell infusion. On day 0, all patients received CAR T cell infusion (3 × 10⁵ to 10 × 10⁵ per kg body weight). The doses were determined based on our previous studies and are described in Table 1. Once complete remission (CR) was achieved, some patients received consolidative hematopoietic stem cell transplantation (allo-HSCT).

Robust expansion and persistence of genetically modified T cells in vivo are critical for durable clinical remissions in patients with hematologic malignancies [4]. Previous studies report that exposure to CD19 protein in vivo can trigger the proliferation of CD19 CAR T cells [5]. Therefore, we first evaluated the expansion and persistence of infused CAR-T cells in the blood by flow cytometry (FCM). As shown in Figure 1A, infused CAR-T cell expansion peaked from day 7 to 17 in peripheral blood (PB). The median peak of the CAR T cells as a percentage of total lymphocytes was in the range of 3%–33.29%, and a rapid decline followed. The results indicated that CD19 CAR T cells had successfully expanded in most of the isolated EM-ALL patients, although at a comparatively lower level than those with leukemia blasts in bone marrow (BM) or PB or both (data not shown).

As for the persistence, dynamic FCM analysis showed that CAR T cells in PB persisted for ≤20 days and the percentage of CD19 CAR T cells of total lymphocytes decreased rapidly in most of the isolated
**TABLE 1**  Patient characteristics and clinical outcome of CAR T infusion

| Patient | Age (Years) | Gender | Site of extramedullary involvement | Previous transplant (Y/N) | WBC at diagnosis (10^9/L) | Fusion gene/mutation | Refractory/relapsed | Cell dose (x10^5/kg) | Response after CAR T cell infusion (days) | EMDs elimination (Y/N) | Best Response/LFS (months) |
|---------|-------------|--------|-----------------------------------|---------------------------|---------------------------|----------------------|--------------------|---------------------|------------------------------------------|------------------------|--------------------------|
| 1       | 12          | F      | bone, diffused                    | N                         | 9.61                      | None                 | Relapsed           | 3                   | CR/MRD-(28)                              | Y                      | CR/7                     |
| 2       | 33          | F      | liver, CNS, diffused              | N                         | 6.36                      | None                 | Relapsed           | 3                   | CR/MRD-(28)                              | Y                      | CR/5                     |
| 3       | 8           | F      | CNS                               | N                         | 2.63                      | None                 | Relapsed           | 3                   | CR/MRD-(28)                              | Y                      | CR/12                    |
| 4       | 12          | M      | CNS                               | Y                         | 6.32                      | TEL-AML1             | Relapsed           | 10                  | CR/MRD-(28)                              | Y                      | CR/24                    |
| 5       | 13          | M      | CNS, testis                       | N                         | 3.83                      | None                 | Relapsed           | 3                   | CR/MRD-(28)                              | Y                      | CR/24                    |
| 6       | 14          | M      | CNS                               | Y                         | 5.92                      | None                 | Relapsed           | 10                  | CR/MRD-(28)                              | Y                      | CR/27                    |
| 7       | 14          | F      | bone, diffused                    | N                         | 6.41                      | None                 | Relapsed           | 10                  | CR/MRD-(28)                              | Y                      | CR/15                    |
| 8       | 28          | M      | testis, diffused                  | N                         | 5.36                      | TP53                 | Relapsed           | 10                  | CR/MRD-(28)                              | Y                      | CR/4                     |
| 9       | 31          | M      | CNS, liver                        | N                         | 3.84                      | None                 | Refractory         | 3                   | CR/MRD-(28)                              | Y                      | CR/17                    |

Abbreviations: CAR T, chimeric antigen receptor; CR, complete remission; EMDs, extramedullary disease; F, female; LFS, leukemia-free survival; M, male; MRD, minimal residual disease; N, no; ND, not detected; WBC, white blood cell count; Y, yes.

EM-ALL patients (Figure 1A, usually more rapidly than those with leukemia blasts in BM or PB or both based on our other studies, in the paper). CAR T cells in patient 6 were barely detectable on day 14 after infusion. CAR T cell percentage of total lymphocytes in the other eight patients also dropped below 2% on day 20 after infusion. This short duration in PB might be due to the lack of CD19 stimulation in PB or BM, further confirming that CD19 positive blasts in BM and PB not only can trigger CD19 CAR T cell proliferation but also help maintain its persistence, which is consistent with the previous view that circulating antigen is an important factor in the proliferation and persistence of CAR T cells in vivo.

The trafficking of CAR T cells to tumor sites is necessary to their antitumor activity [6, 7]. As shown in Figure 1B, approximately 15.8% CD3+CAR19+ T cells were also observed in the CSF of patient 2 by FCM on day 15 after infusion, indicating the potential ability of CAR T cells trafficking to EM sites, even crossing the blood–brain barrier to eradicate the blasts in the CSF. The high percentage of CD19 CAR T cells in BM aspirates also supported that CD19 CAR T cells could efficiently migrate to the bone marrow (Figure 1B). Consistent with the appearance in the EM sites of CAR T cells, repeated positron emission tomography/computed tomography (PET/CT) showed no evidence of abnormal 18F-fluorodeoxyglucose (FDG) uptake in corresponding lesions of EMDs compared to initial scans (Figure 1C,D). Consequently, all the patients in this study achieved FCM–minimal residual disease (MRD) –negative complete response (CR) on day 30 after CAR-T cell infusion judged by flow cytometry and PET/CT.

Safety is another concern for CAR T-cell therapy, especially in patients with CNS involvement. All nine patients had low grades of CRS (Gr1/2), which were self-limited and needed no specific treatment. Patient 8 developed grade 1 neurotoxicity and successfully recovered with interventions. Other adverse events, especially neurotoxicity in central nervous system leukemia (CNSL) related to CAR T therapy were not observed. These findings suggested that CD19 CAR T cells efficiently eradicated isolated extramedullary leukemia and were well tolerated in these patients, even those patients with CNS involvement.

There is still controversy about whether allo-HSCT is necessary for r/r B-ALL patients after CAR T therapy. [8] Some findings have indicated no difference in leukemia-free survival (LFS) between the patients that underwent allo-HSCT after CAR T therapy and those who did not. [9] while other studies observed that bridging into allo-HSCT after CAR T therapy could improve LFS in r/r B-ALL patients. [10, 11] In this study, as shown in Table S1, once achieved CR after CAR T-cell treatment, 6/9 of the patients proceeded to consolidative allo-HSCT. The follow-up results showed that 3/6 of the allo-HSCT group remained CR within 17 months after CAR T infusion, and the 1-year LFS was 66.7%, while in the non-allo-HSCT group, both patient 2 and patient 8 relapsed within one year after CAR T infusion and the 1-year LFS was 33.3%. Despite there being no significant difference due to the small-sample size, the higher LFS rate in the allo-HSCT group implies that CAR T therapy bridging to allo-HSCT can significantly enhance the clinical outcome for isolated EM-ALL patients.
In summary, based on this study, we envision that CAR T-cell therapy combining allo-HSCT is a safe and feasible regimen and offers new hope for these patients. However, only a small number of patients were enrolled in this study, and more cases and further studies are needed to verify these findings.

ACKNOWLEDGMENTS
We thank the patients who participated in this study and their families, the staff in the laboratory for immunotherapy from the Lu Daopei Hospital, the physicians in the Hematology Department for providing clinical consultation and care, and all the nurses for their devotion and care.

This study was funded by Kecellitics Biotech Company, a subsidiary of the Daopei Medical Group.

CONFLICT OF INTEREST
The authors declare that there is no conflict of interest that could be perceived as prejudicing the impartiality of the research reported.

AUTHOR CONTRIBUTIONS
Peihua Lu, Bo Chen, and Xiangqun Li designed the clinical trial. Kylan Chen, Xian Zhang, Junfang Yang, Jianwei Zheng, Fei Dong, Yongbo Zhu, and Jiao Yu executed the clinical trial and collected the data. Xiangqun Li analyzed the data and wrote the paper.

ETHICAL APPROVAL
This study was conducted according to the principles of the Declaration of Helsinki and with the approval of the Ethics Committee of Daopei Hospital.

All the enrolled patients or their families provided informed consent.

ORCID
Bo Chen https://orcid.org/0000-0002-8878-3032

REFERENCES
1. An F, Wang H, Liu Z, Wu F, Zhang J, Tao Q, et al. Influence of patient characteristics on chimeric antigen receptor T-cell therapy in B-cell acute lymphoblastic leukemia. Nat Commun. 2020;11:5928.
2. Fragoso R, Pereira T, Wu Y, Zhu Z, Cabeçadas José, Dias S. VEGFR-1 (FLT-1) activation modulates acute lymphoblastic leukemia localization and survival within the bone marrow, determining the onset of extramedullary disease. Blood. 2006;107:1608-16.
3. Bertamini L, Nanni J, Marconi G, Abbenante M, Robustelli V, Bacci F, et al. Inotuzumab ozogamicin is effective in relapsed/refractory extramedullary B acute lymphoblastic leukemia. BMC Cancer. 2018;18:1117.

4. Baird JH, Frank MJ, Craig J, Patel S, Spiegel JY, Sahaf B, et al. CD22-directed CAR T-cell therapy induces complete remissions in CD19-directed CAR-refractory large B-cell lymphoma. Blood. 2020;137:2321-2325.

5. Brudno JN, Somerville RPT, Shi V, Rose JJ, Halverson DC, Fowler DH, et al. Allogeneic T cells that express an anti-CD19 chimeric antigen receptor induce remissions of B-cell malignancies that progress after allogeneic hematopoietic stem-cell transplantation without causing graft-versus-host disease. J Clin Oncol. 2016;34:1112–21.

6. Rubinstein JD, Krupski C, Nelson AS, O’brien MM, Davies SM, Phillips CL. Chimeric antigen receptor T cell therapy in patients with multiply relapsed or refractory extramedullary leukemia. Biol Blood Marrow Transplant. 2020;26:e280–e85.

7. Wang Z, Guo Y, Han W. Current status and perspectives of chimeric antigen receptor modified T cells for cancer treatment. Protein Cell. 2017;8:896–925.

8. Zhang X, Lu X-A, Yang J, Zhang G, Li J, Song L, et al. Efficacy and safety of anti-CD19 CAR T-cell therapy in 110 patients with B-cell acute lymphoblastic leukemia with high-risk features. Blood Adv. 2020;4:2325–38.

9. Park JH, Rivière I, Gonen M, Wang X, Sénéchal B, Curran KJ, et al. Long-term follow-up of CD19 CAR therapy in acute lymphoblastic leukemia. N Engl J Med. 2018;378:449–59.

10. Hay KA, Gauthier J, Hirayama AV, Voutsinas JM, Wu Q, Li D, et al. Factors associated with durable EFS in adult B-cell ALL patients achieving MRD-negative CR after CD19 CAR T-cell therapy. Blood. 2019;133:1652–63.

11. Davila ML, Riviere I, Wang X, Bartido S, Park J, Curran K, et al. Efficacy and toxicity management of 19-28z CAR T cell therapy in B cell acute lymphoblastic leukemia. Sci Transl Med. 2014;6:224ra25.

SUPPORTING INFORMATION
Additional supporting information may be found in the online version of the article at the publisher’s website.

How to cite this article: Li X, Chen K, Zhang X, Yang J, Zheng J, Dong F, et al. Successful therapy of chimeric antigen receptor T cells for isolated extramedullary acute lymphoblastic leukemia. eJHaem. 2022;3:571–574. https://doi.org/10.1002/jha.2411